Anzeige
Mehr »
Login
Freitag, 04.04.2025 Börsentäglich über 12.000 News von 693 internationalen Medien
Ist das der Durchbruch für den KI-Biotech-Geheimtipp?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
289 Leser
Artikel bewerten:
(1)

Charlotte Casebourne Stock moves on from Theolytics to next entrepreneurial endeavour

Finanznachrichten News

OXFORD, England, July 12, 2024 /PRNewswire/ -- Today Theolytics, a clinical stage biotechnology company harnessing viruses to combat disease, announced that Charlotte Casebourne Stock, Co-Founder and CEO, has decided to transition into an advisory role with the company. Mike Grey, Executive Chair of the board of directors will assume overall leadership responsibility until further notice.

Charlotte Casebourne Stock moves on from Theolytics to next entrepreneurial endeavour

Charlotte Casebourne Stock shares: "It's been extremely rewarding leading Theolytics from idea at inception in 2017 to dosing the first ovarian cancer patient with our lead oncolytic virus candidate THEO-260 this year. I set out on my entrepreneurial journey to drive equitable access to healthcare innovation, and to create sustainable companies. With the progress made, and our investors' support for Theolytics' lead clinical program, it is the right time for me to embark on a new chapter, in line with my personal mission."

Mike Grey commented: "On behalf of the board and Theolytics' investors we would like to extend our heartfelt appreciation to Charlotte. Without her, Theolytics wouldn't be in the strong position the company finds itself in today. Under Charlotte's leadership, over $40m of dilutive and non-dilutive capital was raised, and in only seven years the company has advanced into the clinic. We respect her decision to pursue new entrepreneurial endeavors, and wish her the very best. I look forward to working with her as an advisor, alongside Theolytics' Board and team to execute on the promising strategy defined."

About Theolytics

Theolytics is working to develop next generation oncolytic viral therapies, pioneering a new approach to develop efficacious, targeted candidates suitable for systemic intravenous delivery. The company is focused on the clinical development of its lead program, with the ambition of providing better outcomes for patients with ovarian cancer. Theolytics is backed by international life sciences investors M Ventures, Taiho Ventures, Epidarex Capital, Oxford Science Enterprises, Sound Bioventures and The University of Oxford.

Photo - https://mma.prnewswire.com/media/2455984/Theolytics.jpg

CONTACT: enquiries@theolytics.com

Cision View original content:https://www.prnewswire.co.uk/news-releases/charlotte-casebourne-stock-moves-on-from-theolytics-to-next-entrepreneurial-endeavour-302192046.html

© 2024 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.